Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone

Archives of Toxicology

Volumn 91, Issue 4, 2017, Pages 1957-1975

  Arlt, Volker M ^a   Meinl, Walter ^b   Florian, Simone ^b   Nagy, Eszter ^a   Barta, Frantisek ^c   Thomann, Marlies ^a   Mrizova, Iveta ^c   Krais, Annette M ^a,d   Liu, Maggie ^e   Richards, Meirion ^e   Mirza, Amin ^e   Kopka, Klaus ^f   Phillips, David H ^a   Glatt, Hansruedi ^b,g   Stiborova, Marie ^c   Schmeiser, Heinz H ^f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

^d LUND UNIVERSITY   (Sweden)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

3 Nitrobenzanthrone; Aristolochic acid nephropathy; Balkan endemic nephropathy; Carcinogen metabolism; DNA adducts; Sulfotransferase 1A1

Indexed keywords

2 NAPHTHOL; 3 NITROBENZANTHRONE; ARISTOLOCHIC ACID; NQO1 PROTEIN; PHOSPHORUS 32; PROTEIN; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; UNCLASSIFIED DRUG; 3-NITROBENZANTHRONE; ARYL SULFOTRANSFERASE; BENZ[A]ANTHRACENE DERIVATIVE; CARCINOGEN; DNA ADDUCT; SULT1A1 PROTEIN, HUMAN; SULT1A2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; COLON; CONTROLLED STUDY; CYTOSOL; CYTOSOLIC FRACTION; DNA ADDUCT; DNA BINDING; DNA MODIFICATION; ENZYME ACTIVITY; FORESTOMACH; GENE CLUSTER; GENOTOXICITY; GENOTYPE; GLANDULAR STOMACH; IN VITRO STUDY; KIDNEY; LIVER; LUNG; MALE; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; DRUG EFFECTS; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MULTIGENE FAMILY;

ANIMALS; ARISTOLOCHIC ACIDS; ARYLSULFOTRANSFERASE; BENZ(A)ANTHRACENES; CARCINOGENS; CYTOSOL; DNA ADDUCTS; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIGENE FAMILY;

EID: 84983420827     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-016-1808-6     Document Type: Article

References (68)

1. Alnouti Y, Klaassen CD (2006) Tissue distribution and ontogeny of sulfotransferase enzymes in mice. Toxicol Sci 93(2):242–255
2. Arlt VM (2005) 3-Nitrobenzanthrone, a potential human cancer hazard in diesel exhaust and urban air pollution: a review of the evidence. Mutagenesis 20(6):399–410
3. Arlt VM, Bieler CA, Mier W, Wiessler M, Schmeiser HH (2001) DNA adduct formation by the ubiquitous environmental contaminant 3-nitrobenzanthrone in rats determined by (32)P-postlabeling. Int J Cancer 93(3):450–454
4. Arlt VM, Ferluga D, Stiborova M et al (2002a) Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101(5):500–502
5. Arlt VM, Glatt H, Muckel E et al (2002b) Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Carcinogenesis 23(11):1937–1945
6. Arlt VM, Stiborova M, Schmeiser HH (2002c) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17(4):265–277
7. Arlt VM, Glatt H, Muckel E et al (2003) Activation of 3-nitrobenzanthrone and its metabolites by human acetyltransferases, sulfotransferases and cytochrome P450 expressed in Chinese hamster V79 cells. Int J Cancer 105(5):583–592
8. Arlt VM, Stiborova M, Henderson CJ et al (2005) Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res 65(7):2644–2652
9. Arlt VM, Schmeiser HH, Osborne MR et al (2006) Identification of three major DNA adducts formed by the carcinogenic air pollutant 3-nitrobenzanthrone in rat lung at the C8 and N2 position of guanine and at the N6 position of adenine. Int J Cancer 118(9):2139–2146
10. Arlt VM, Stiborova M, vom Brocke J et al (2007) Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28(11):2253–2261
11. Arlt VM, Stiborova M, Henderson CJ et al (2008) Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29(3):656–665
12. Arlt VM, Levova K, Barta F et al (2011) Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1−/−, Cyp1a2−/−, and Cyp1a1/1a2−/− mice. Chem Res Toxicol 24(10):1710–1719
13. Arlt VM, Poirier MC, Sykes SE et al (2012) Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling. Toxicol Lett 213(2):160–166
14. Arlt VM, Henderson CJ, Wolf CR, Stiborova M, Phillips DH (2015a) The Hepatic Reductase Null (HRN) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants. Toxicol Res 4(3):548–562
15. Arlt VM, Krais AM, Godschalk RW et al (2015b) Pulmonary inflammation impacts on CYP1A1-mediated respiratory tract DNA damage induced by the carcinogenic air pollutant benzo[a]pyrene. Toxicol Sci 146:213–225
16. Baudoux TE, Pozdzik AA, Arlt VM et al (2012) Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int 82(10):1105–1113
17. Bendadani C, Meinl W, Monien B et al (2014a) Determination of sulfotransferase forms involved in the metabolic activation of the genotoxicant 1-hydroxymethylpyrene using bacterially expressed enzymes and genetically modified mouse models. Chem Res Toxicol 27(6):1060–1069
18. Bendadani C, Meinl W, Monien BH, Dobbernack G, Glatt H (2014b) The carcinogen 1-methylpyrene forms benzylic DNA adducts in mouse and rat tissues in vivo via a reactive sulphuric acid ester. Arch Toxicol 88(3):815–821
19. Bieler CA, Stiborova M, Wiessler M, Cosyns JP, van Ypersele de Strihou C, Schmeiser HH (1997) 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18(5):1063–1067
20. Chan W, Cui L, Xu G, Cai Z (2006) Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20(11):1755–1760
21. Chan W, Luo HB, Zheng Y, Cheng YK, Cai Z (2007) Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metab Dispos 35:866–874
22. Dobbernack G, Meinl W, Schade N et al (2011) Altered tissue distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adducts in mice transgenic for human sulfotransferases 1A1 and 1A2. Carcinogenesis 32(11):1734–1740
23. Frame LT, Ozawa S, Nowell SA et al (2000) A simple colorimetric assay for phenotyping the major human thermostable phenol sulfotransferase (SULT1A1) using platelet cytosols. Drug Metab Dispos 28(9):1063–1068
24. Glatt H, Meinl W (2004) Use of genetically manipulated Salmonella typhimurium strains to evaluate the role of sulfotransferases and acetyltransferases in nitrofen mutagenicity. Carcinogenesis 25(5):779–786
25. Glatt H, Sabbioni G, Monien BH, Meinl W (2016) Use of genetically manipulated Salmonella typhimurium strains to evaluate the role of human sulfotransferases in the bioactivation of nitro- and aminotoluenes. Environ Mol Mutagen 57(4):299–311
26. Gokmen MR, Cosyns JP, Arlt VM et al (2013) The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Int Med 158(6):469–477
27. Herrmann K, Engst W, Meinl W et al (2014) Formation of hepatic DNA adducts by methyleugenol in mouse models: drastic decrease by Sult1a1 knockout and strong increase by transgenic human SULT1A1/2. Carcinogenesis 35(4):935–941
28. Krais AM, Muhlbauer KR, Kucab JE et al (2015) Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts. Toxicol In Vitro 29(1):34–43
29. Krais AM, Speksnijder EN, Melis JP et al (2016a) The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice. Arch Toxicol 90(4):839–851
30. Krais AM, Speksnijder EN, Melis JP et al (2016b) Metabolic activation of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine and DNA adduct formation depends on p53: studies in Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice. Int J Cancer 138(4):976–982
31. Krumbiegel G, Hallensleben J, Mennicke WH, Rittmann N, Roth HJ (1987) Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17(8):981–991
32. Kucab JE, Zwart EP, van Steeg H et al (2016) TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts. DNA Repair 39:21–33
33. Levova K, Moserova M, Kotrbova V et al (2011) Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci 121(1):43–56
34. Levova K, Moserova M, Nebert DW et al (2012) NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I. Toxicol Appl Pharmacol 265(3):360–367
35. Lord GM, Hollstein M, Arlt VM et al (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43(4):e11–e17
36. Martin FL, Patel II, Sozeri O et al (2010) Constitutive expression of bioactivating enzymes in normal human prostate suggests a capability to activate pro-carcinogens to DNA-damaging metabolites. Prostate 70(14):1586–1599
37. Martinek V, Kubickova B, Arlt VM et al (2011) Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuro Endocrinol Lett 32(Suppl 1):57–70
38. Meinl W, Pabel U, Osterloh-Quiroz M, Hengstler JG, Glatt H (2006) Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer 118(5):1090–1097
39. Mengs U, Lang W, Poch JA (1982) The carcinogenic action of aristolochic acid in rats. Arch Toxicol 51(2):107–119
40. Mizerovska J, Dracinska H, Frei E, Schmeiser HH, Arlt VM, Stiborova M (2011) Induction of biotransformation enzymes by the carcinogenic air-pollutant 3-nitrobenzanthrone in liver, kidney and lung, after intra-tracheal instillation in rats. Mutat Res 720(1–2):34–41
41. Nebert DW, Shi Z, Galvez-Peralta M, Uno S, Dragin N (2013) Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences–Cyp1 knockout mouse lines as a paradigm. Mol Pharmacol 84(3):304–313
42. Nik-Zainal S, Kucab JE, Morganella S et al (2015) The genome as a record of environmental exposure. Mutagenesis 30(6):763–770
43. Nortier JL, Martinez MC, Schmeiser HH et al (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342(23):1686–1692
44. Odell AF, Odell LR, Askham JM, Alogheli H, Ponnambalam S, Hollstein M (2013) A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J Biol Chem 288(23):16704–16714
45. Phillips DH (2013) On the origins and development of the (32)P-postlabelling assay for carcinogen-DNA adducts. Cancer Lett 334(1):5–9
46. Phillips DH, Arlt VM (2014) 32P-postlabeling analysis of DNA adducts. Meth Mol Biol 1105:127–138
47. Poon SL, Pang ST, McPherson JR et al (2013) Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 5(197):197ra101
48. Rendic S, Guengerich FP (2012) Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25(7):1316–1383
49. Sachse B, Meinl W, Glatt H, Monien BH (2014) The effect of knockout of sulfotransferases 1a1 and 1d1 and of transgenic human sulfotransferases 1A1/1A2 on the formation of DNA adducts from furfuryl alcohol in mouse models. Carcinogenesis 35(10):2339–2345
50. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 56(9):2025–2028
51. Schmeiser HH, Stiborova M, Arlt VM (2009) Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Dis Devel 12(1):141–148
52. Schmeiser HH, Kucab JE, Arlt VM et al (2012) Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ Mol Mutagen 53(8):636–641
53. Schmeiser HH, Stiborova M, Arlt VM (2013) (32)P-postlabeling analysis of DNA adducts. Methods Mol Biol 1044:389–401
54. Schmeiser HH, Nortier JL, Singh R et al (2014) Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 135(2):502–507
55. Sidorenko VS, Attaluri S, Zaitseva I et al (2014) Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis 35(8):1814–1822
56. Stiborova M, Frei E, Wiessler M, Schmeiser HH (2001a) Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem Res Toxicol 14(8):1128–1137
57. Stiborova M, Hajek M, Frei E, Schmeiser HH (2001b) Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen Physiol Biophys 20(4):375–392
58. Stiborova M, Frei E, Sopko B, Wiessler M, Schmeiser HH (2002) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23(4):617–625
59. Stiborova M, Frei E, Sopko B et al (2003) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H: quinone oxidoreductase. Carcinogenesis 24(10):1695–1703
60. Stiborova M, Frei E, Hodek P, Wiessler M, Schmeiser HH (2005) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113(2):189–197
61. Stiborova M, Mareis J, Frei E, Arlt VM, Martinek V, Schmeiser HH (2011) The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H: quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen 52(6):448–459
62. Stiborova M, Levova K, Barta F et al (2012) Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci 125(2):345–358
63. Stiborova M, Martinek V, Frei E, Arlt VM, Schmeiser HH (2013) Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab 14(6):695–705
64. Stiborova M, Frei E, Arlt VM, Schmeiser HH (2014a) Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica 44(2):135–145
65. Stiborova M, Frei E, Schmeiser HH, Arlt VM, Martinek V (2014b) Mechanisms of enzyme-catalyzed reduction of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and aristolochic acid I: experimental and theoretical approaches. Int J Mol Sci 15(6):10271–10295
66. Teubner W, Meinl W, Florian S, Kretzschmar M, Glatt H (2007) Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 404(2):207–215
67. Wang Y, Arlt VM, Roufosse CA et al (2012) ACB-PCR measurement of H-ras codon 61 CAA → CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues. Environ Mol Mutagen 53(7):495–504
68. Wohak LE, Krais AM, Kucab JE et al (2016) Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53-dependent mechanism. Arch Toxicol 90(2):291–304